The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue

Aarde, 2013, Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats, Addict. Biol., 18, 786, 10.1111/adb.12038 Aarde, 2013, The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats, Neuropharmacology, 71, 130, 10.1016/j.neuropharm.2013.04.003 Aarde, 2015, In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats, Psychopharmacology, 232, 3045, 10.1007/s00213-015-3944-8 Abreu, 2001, Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans, Psychopharmacology, 154, 76, 10.1007/s002130000624 Bäckberg, 2014, Intoxications of the new psychoactive substance 5-(2-aminopropyl)indole (5-IT): a case series from the Swedish STRIDA project, Clin. Toxicol., 52, 6618, 10.3109/15563650.2014.920088 Banks, 2014, Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys, Exp. Clin. Psychopharmacol., 22, 274, 10.1037/a0036595 Baumann, 2004, Effects of “Legal X” piperazine analogs on dopamine and serotonin release in rat brain, Ann. N. Y. Acad. Sci., 1025, 189, 10.1196/annals.1316.024 Baumann, 2011, In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat, J. Pharmacol. Exp. Ther., 337, 218, 10.1124/jpet.110.176271 Baumann, 2012, The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue, Neuropsychopharmacology, 37, 1192, 10.1038/npp.2011.304 Baumann, 2013, Psychoactive “bath salts”: not so soothing, Eur. J. Pharmacol., 698, 1, 10.1016/j.ejphar.2012.11.020 Baumann, 2013, Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive “bath salts” products, Neuropsychopharmacology, 38, 552, 10.1038/npp.2012.204 Baumann, 2014, Baths salts, spice, and related designer drugs: the science behind the headlines, J. Neurosci., 34, 15150, 10.1523/JNEUROSCI.3223-14.2014 Blough, 2014, Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes, Psychopharmacology, 231, 4135, 10.1007/s00213-014-3557-7 Bossong, 2010, mCPP: an undesired addition to the ecstasy market, J. Psychopharmacol., 24, 1395, 10.1177/0269881109102541 Bowen, 1996, Functional observational battery comparing effects of ethanol, 1,1,1-trichloroethane, ether, and flurothyl, Neurotoxicol. Teratol., 18, 577, 10.1016/0892-0362(96)00064-5 Boyer, 2005, The serotonin syndrome, N. Engl. J. Med., 352, 1112, 10.1056/NEJMra041867 Brunt, 2011, Instability of the ecstasy market and a new kid on the block: mephedrone, J. Psychopharmacol., 25, 1543, 10.1177/0269881110378370 Brunt, 2012, Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users, Psychopharmacology, 220, 751, 10.1007/s00213-011-2529-4 Cerletti, 1968, Pharmacologic studies on the structure-activity relationship of hydroxyindole alkylamines, Adv. Pharmacol., 6, 233, 10.1016/S1054-3589(08)60322-1 Coppola, 2013, A new stimulant of abuse: 5-(2-aminopropyl) indole, Am. J. Psychiatry, 170, 226, 10.1176/appi.ajp.2012.12091168 Creehan, 2015, Intravenous self-administration of mephedrone, methylone and MDMA in female rats, Neuropharmacology, 92, 90, 10.1016/j.neuropharm.2015.01.003 Elliott, 2013, AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis, Drug Test. Anal., 5, 196, 10.1002/dta.1420 Eshleman, 2013, Substituted methcathinones differ in transporter and receptor interactions, Biochem. Pharmacol., 85, 1803, 10.1016/j.bcp.2013.04.004 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2013 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2013 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2014 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2015 Fantegrossi, 2005, Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys, Drug Alcohol Depend., 77, 161, 10.1016/j.drugalcdep.2004.07.014 Fantegrossi, 2008, A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse, Neuroscience, 151, 533, 10.1016/j.neuroscience.2007.11.007 Fantegrossi, 2013, In vivo effects of abused ‘bath salt’ constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity, Neuropsychopharmacology, 38, 563, 10.1038/npp.2012.233 Filip, 2010, Behavioral evidence for the significance of serotoninergic (5-HT) receptors in cocaine addiction, Addict. Biol., 15, 227, 10.1111/j.1369-1600.2010.00214.x Fischman, 1989, Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs, NIDA Res. Monogr., 92, 211 German, 2014, Bath salts and synthetic cathinones: an emerging designer drug phenomenon, Life Sci., 97, 2, 10.1016/j.lfs.2013.07.023 Glennon, 2014, Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention, 581, 10.1016/B978-0-12-420118-7.00015-9 Green, 2003, The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”), Pharmacol. Rev., 55, 463, 10.1124/pr.55.3.3 Herraiz, 2014, 5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO), Drug Test. Anal., 6, 607, 10.1002/dta.1530 Hill, 2011, Clinical toxicology of newer recreational drugs, Clin. Toxicol., 49, 705, 10.3109/15563650.2011.615318 Hofmann A, Troxler F (1963) Nouveaux dérivés de l'indole et leur préparation (patent). FR1344579. Howell, 2015, Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder, Pharmacol. Rev., 67, 176, 10.1124/pr.114.009514 Iversen, 2014, Designer psychostimulants: pharmacology and differences, Neuropharmacology, 87, 59, 10.1016/j.neuropharm.2014.01.015 López-Arnau, 2013, An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts”, Prog. Neuropsychopharmacol. Biol. Psychiatry, 45, 64, 10.1016/j.pnpbp.2013.04.007 Ma, 2008, Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats, Eur. J. Pharmacol., 588, 198, 10.1016/j.ejphar.2008.04.004 Marusich, 2012, Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice, Neurotoxicology, 33, 1305, 10.1016/j.neuro.2012.08.003 Marusich, 2014, Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV), Neuropharmacology, 87, 206, 10.1016/j.neuropharm.2014.02.016 Miotto, 2013, Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports, Drug Alcohol Depend., 132, 1, 10.1016/j.drugalcdep.2013.06.016 Montgomery, 2007, Comparative potencies of 3, 4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H] noradrenaline and [3H] 5-HT transport in mammalian cell lines, Br. J. Pharmacol., 152, 1121, 10.1038/sj.bjp.0707473 National Research Council Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research, 2011 Negus, 2007, Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate “agonist” medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys, J. Pharmacol. Exp. Ther., 320, 627, 10.1124/jpet.106.107383 Negus, 2014, Intracranial self-stimulation to evaluate abuse potential of drugs, Pharmacol. Rev., 66, 869, 10.1124/pr.112.007419 Nelson, 2006, Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans, Drug Alcohol Depend., 82, 19, 10.1016/j.drugalcdep.2005.08.004 Reith, 2015, Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter, Drug Alcohol Depend., 147, 1, 10.1016/j.drugalcdep.2014.12.005 Rosenbaum, 2012, Here today, gone tomorrow… and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines, J. Med. Toxicol., 8, 15, 10.1007/s13181-011-0202-2 Rothman, 2003, Monoamine transporters and psychostimulant drugs, Eur. J. Pharmacol., 479, 23, 10.1016/j.ejphar.2003.08.054 Rothman, 2006, Balance between dopamine and serotonin release modulates behavioral effects of Amphetamine-Type drugs, Ann. N. Y. Acad. Sci., 1074, 245, 10.1196/annals.1369.064 Rothman, 2007, Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions, AAPS J., 9, E1, 10.1208/aapsj0901001 Rothman, 2003, In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates, J. Pharmacol. Exp. Ther., 307, 138, 10.1124/jpet.103.053975 Scott, 2014, Identification of (2-aminopropyl)indole positional isomers in forensic samples, Drug Test. Anal., 6, 598, 10.1002/dta.1508 Seetohul, 2013, Four fatalities involving 5-IT, J. Anal. Toxicol., 37, 447, 10.1093/jat/bkt053 Shanks, 2012, Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry, J. Anal. Toxicol., 36, 360, 10.1093/jat/bks047 Silins, 2007, Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk, Aust. N. Z. J. Psychiatry, 41, 649, 10.1080/00048670701449237 Simmler, 2013, Pharmacological characterization of designer cathinones in vitro, Br. J. Pharmacol., 168, 458, 10.1111/j.1476-5381.2012.02145.x Simmler, 2014, Monoamine transporter and receptor interaction profiles of a new series of designer cathinones, Neuropharmacology, 79, 152, 10.1016/j.neuropharm.2013.11.008 Sitte, 2015, Amphetamines, new psychoactive drugs and the monoamine transporter cycle, Trends Pharmacol. Sci., 36, 41, 10.1016/j.tips.2014.11.006 Troxler, 1968, Synthesen von Indolen mit (2-Aminoäthyl)-, (2-Aminopropyl)-oder Alkanolamin-Seitenketten am Sechsring. 5. Mitt. über synthetische Indol-Verbindungen, Helv. Chim. Acta, 51, 1616, 10.1002/hlca.19680510717 United Nations Office on Drugs and Crime (UNODC), 2014, 2014 U.S. Environmental Protection Agency (U.S. EPA), 1998 U.S. Environmental Protection Agency (U.S. EPA), 1998 Watterson, 2012, The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in “bath salts”, J. Addict. Res. Ther. Watterson, 2014, Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV), Addict. Biol., 19, 165, 10.1111/j.1369-1600.2012.00474.x Wee, 2005, Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs, J. Pharmacol. Exp. Ther., 313, 848, 10.1124/jpet.104.080101 Wise, 1987, A psychomotor stimulant theory of addiction, Psychol. Rev., 94, 469, 10.1037/0033-295X.94.4.469 Woolverton, 2004, Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine, Eur. J. Pharmacol., 486, 251, 10.1016/j.ejphar.2004.01.003 Yarosh, 2007, MDMA-like behavioral effects of N-substituted piperazines in the mouse, Pharmacol. Biochem. Behav., 88, 18, 10.1016/j.pbb.2007.06.007